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Abstract
Background:  Candidate gene and genome-wide association studies have both reproducibly
identified several common Single Nucleotide Polymorphisms (SNPs) that confer type 2 diabetes
(T2D) risk in European populations. Our aim was to evaluate the contribution to T2D of five of
these established T2D-associated loci in the Arabic population from Tunisia.
Methods: A case-control design comprising 884 type 2 diabetic patients and 513 control subjects
living in the East-Center of Tunisia was used to analyze the contribution to T2D of the following
SNPs: E23K in KCNJ11/Kir6.2, K121Q in ENPP1, the -30G/A variant in the pancreatic β-cell specific
promoter of Glucokinase, rs7903146 in TCF7L2  encoding transcription factor 7-like2, and
rs7923837 in HHEX encoding the homeobox, hematopoietically expressed transcription factor.
Results: TCF7L2-rs7903146 T allele increased susceptibility to T2D (OR = 1.25 [1.06–1.47], P =
0.006) in our study population. This risk was 56% higher among subjects carrying the TT genotype
in comparison to those carrying the CC genotype (OR = 1.56 [1.13–2.16], P = 0.002). No allelic or
genotypic association with T2D was detected for the other studied polymorphisms.
Conclusion: In the Tunisian population, TCF7L2-rs7903146 T allele confers an increased risk of
developing T2D as previously reported in the European population and many other ethnic groups.
In contrast, none of the other tested SNPs that influence T2D risk in the European population was
associated with T2D in the Tunisian Arabic population. An insufficient power to detect minor allelic
contributions or genetic heterogeneity of T2D between different ethnic groups can explain these
findings.
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Background
T2D is a complex metabolic disorder which is caused by
both decreased insulin sensitivity, and impaired insulin
secretion due to pancreatic β-cell defects [1]. T2D is
thought to result from the effects of environmental and
lifestyle risk factors together with at-risk genetic variants
in predisposed individuals [2].
T2D is a global major health problem showing worldwide
increasing prevalence [3]. The Arabic population is how-
ever particularly targeted by T2D [4,5]. In the Tunisian
population, the prevalence of T2D reaches 9% of adults
[6] that is much higher compared with European popula-
tions and may be due to the specificity of the Tunisian life
style or to a specific genetic background.
From the previous familial linkage and candidate-gene
studies, T2D-associated single nucleotide polymorphisms
(SNPs) have been confirmed and widely replicated, but
with modest effects on disease risk [7,8]. These variants
include the E23K variation in KCNJ11, encoding the
Kir6.2 subunit of the K+-ATP channel [9], the Pro12Ala
variant in PPARG [10], the -30G/A polymorphism in the
β-cell specific promoter of glucokinase (GCK) [8,11], and
the K121Q variant of ENPP1  encoding ectonucleotide
pyrophosphatase phosphodiesterase, the inhibitor of
insulin receptor [12].
The SNP with the largest risk effect is the intronic variant,
rs7903146, in the TCF7L2 locus [13,14]. This association
was consistently replicated in populations of various eth-
nic origins, among which Morrocans [15].
Recently, genome-wide association (GWA) studies
revealed novel SNPs that increased T2D risk in different
European populations [14,16-18]. The French GWA study
detected unexpected association to T2D for non-coding
SNPs at the HHEX locus (homeobox, hematopoietically
expressed) [14], which were also shown to contribute to
an increased risk of T2D in British [18], Japanese [19] and
other Asiatic [20] populations.
In this study, we analyzed five polymorphisms in the fol-
lowing genes, rs7903146 of TCF7L2, rs7923837 of HHEX,
rs1788994 of GCK, rs5219 of KCNJ11/Kir6.2  and
rs1044498 of ENPP1 using a case-control design in 1,397
individuals (884 unrelated T2D patients and 513 normo-
glycemic controls) to assess their association with T2D
risk in the Tunisian population. To our knowledge, four of
them have not been previously tested in this Arabic popu-
lation, and we aim to evaluate whether these common
variants reported to be at-risk for T2D in European popu-
lations may also contribute to T2D risk and aetiology in
the Tunisian population living in the East-Center part of
the country.
Methods
Study population
The T2D group includes 884 unrelated Tunisian diabetic
subjects (406 males, 478 females). The affected individu-
als were recruited in 2003–2006 in collaboration with the
Endocrinology-Diabetology departments of Farhat
Hached Hospital (Sousse, Tunisia) and Fattouma Bour-
guiba University Hospital (Monastir, Tunisia). T2D was
defined according to 1997 American Diabetes Associa-
tion. Inclusion criteria: fasting plasma glucose ≥ 7.0
mmol/l and/or treatment for diabetes included diet and/
or oral antidiabetic drugs and/or insulin to achieve glyc-
emic control. All subjects who required insulin had been
treated with oral drugs for at least 2 years.
The diabetic cases included in the study are representative
of the diabetic population examined in two hospital clin-
ics in the center of Tunisia (Sousse and Monastir, Tunisia)
within a time period of 4 years; no clinical criteria of
exclusion have been held (except patients diagnosed with
type 1 diabetes, and patients with type 2 diabetes diag-
nosed at age ≤ 40 years).
Individual and clinical characteristics were recorded for all
subjects, including age at examination, gender, age at
diagnosis, duration of diabetes, first-degree family history
of diabetes, treatment for diabetes including date of initi-
ation and/or discontinuation of oral agents or insulin.
When available, the following details were obtained from
the clinic records: dyslipidaemia, history of chronic com-
plications of diabetes, history of hypertension, ischaemic
heart disease and other medical illness.
All T2D patients were compared to a group of 513 normo-
glycaemic subjects (fasting glycaemia < 6.1 mmol/l, age at
examination > 45 years, BMI < 30 kg/m2) from blood
donors recruited in the transfusion centres of Monastir
and Sousse (Center of Tunisia). None was first degree rel-
ative of other subjects in the case or control groups; they
were not known to have diabetes although occult disease
was not excluded.
Written informed consent was obtained from all subjects
and DNA was extracted using the standard phenol-chloro-
form procedure. The study protocol was approved by the
University of Monastir (Tunisia).
SNP genotyping
SNP genotyping of rs7903146 in TCF7L2, rs7923837 in
HHEX and rs1799884 in GCK promoter were performed
using allelic discrimination TaqMan SNP Genotyping
Assays (Applied Biosystems, Foster City, California. USA).
The PCR primers and TaqMan probes were designed by
Primer Express and optimized according to the manufac-
turer's protocol. We obtained a 95% genotyping successBMC Medical Genetics 2009, 10:33 http://www.biomedcentral.com/1471-2350/10/33
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rate (except for HHEX rs7923837 which gave a 90% gen-
otyping rate). A random of 10% sample set was re-tested
with the same method to confirm genotype accuracy. No
difference of genotypes was found between the duplicate
samples.
For genotyping of E23K (rs5219) in KCNJ11/Kir6.2 and
K121Q (rs1044498) in ENPP1, we used the FRET technol-
ogy using the Light Cycler TM assay (Roche Diagnostics,
Basel, Switzerland). For both SNPs, the genotyping suc-
cess rate was 91%. In order to assess genotyping accuracy
for these two SNPs, 20 random samples were tested by
direct sequencing, which provided a 100% concordance
rate.
Statistical analysis
Allele frequencies were calculated by the genotype-count-
ing method, and each polymorphism was tested for
Hardy-Weinberg equilibrium using Chi square goodness-
of-fit test using HPlus 2.5 software (see Additional file 1).
Comparison of allele frequencies and genotype distribu-
tions between all T2D and control groups were done using
the Pearson's Chi square test.
Genotypic associations for additive, dominant and reces-
sive models were tested by calculating a logistic regression
(adjustments) statistic and corresponding P value using
the program SNPstats http://bioinfo.iconcologia.net/
index.php?module=Snpstats. The results are expressed as
P value (two-tailed), odds ratio (OR) and 95% confidence
intervals (CI). The minimum detectable effect size with a
statistical power of 80% was assessed [21] using Quanto
software v.1.2.3 http://hydra.usc.edu/GxE.
Student's t-test, used to determine differences in means of
continuous variables in the normoglycemic control sub-
jects, was performed using the SPSS statistical analysis
software v.16.0 (SPSS, Chicago, Illinois, USA). Statistical
significance was set at a P-value < 0.05.
Results
The clinical characteristics of the T2D patients and control
subjects are given in Table 1. Among T2D subjects,
30.09% (n = 266) are obese (BMI ≥ 30 kg/m2) versus
69.91% (n = 618) non-obese (BMI < 30 kg/m2). No sig-
nificant differences in clinical features were noted when
all T2D patients were compared to the non-obese T2D
group (data not shown).
The distribution of allelic and genotypic frequencies of
the five SNPs was compared between the two study groups
(884 T2D cases and 513 normoglycemic controls) (Table
2). The genotype distributions of all SNPs obeyed Hardy
Weinberg equilibrium in the control group (Supplemen-
tary Table).
The T allele of TCF7L2 was significantly associated with
increased risk of T2D and the OR adjusted for age, gender
and BMI was 1.25, 95% IC [1.06–1.47], P = 0.006 (Table
2). The association was observed in all genotypic models
but the highest risk was observed under the additive
model (OR = 1.56, 95% IC [1.13–2.16], P = 0.002) (Table
2).
As shown in Table 2, no other alleles of the remaining var-
iants were associated with an increased risk of T2D in the
Tunisian population.
We estimated the minimum effect sizes detectable with a
statistical power of 80% under different genetic models,
and according to the allelic frequencies of each SNP tested
in our study, as indicated in Table 3. Except for TCF7L2
SNP that showed a significant effect on T2D risk with an
additive OR value above the threshold estimated in our
Table 1: Characteristics of the T2D patients and control subjects from the Tunisian population
Characteristics Controls (n = 513) T2D (n = 884)
Gender (Male/Female) 258/255 406/478
Age at examination (years) 60 ± 8.69 59.42 ± 11.09
Mean BMI (kg/m2) 24.83 ± 2.73 27.82 ± 5.30
Systolic blood pressure (mmHg) 122.12 ± 14.33 139.80 ± 28.13
Diastolic blood pressure (mmHg) 78.18 ± 10.55 80.92 ± 12.73
Fasting glucose (mmol/l) 5.05 ± 0.64 12.67 ± 5.30
HbA1c (%) 4.47 ± 1.23 9.49 ± 3.89
Total cholesterol (mmol/l) 4.64 ± 1.28 5.26 ± 1.42
Triglycerides (mmol/l) 1.18 ± 0.60 1.77 ± 1.31
HDL-cholesterol (mmol/l) 1.27 ± 0.39 1.07 ± 0.38
LDL-cholesterol (mmol/l) 2.59 ± 1.60 3.77 ± 1.37
n: number of total subjects
Data are expressed as means ± SD.
Most of the diabetic patients included in the study were recruited immediately after their admission to the Endocrinology Department, explaining a 
poor control of glycemic levels (mean fasting glucose: 12.67 mmol/l; mean HbA1c: 9.49%) in these subjects.BMC Medical Genetics 2009, 10:33 http://www.biomedcentral.com/1471-2350/10/33
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power calculation, the other four SNPs are known to have
a lower allelic contribution that could not be easily detect-
able in this middle-sized cohort (Table 3).
Discussion
The T-allele of TCF7L2-rs7903146 is associated with an
increased risk in T2D among the Tunisian population.
Recent GWA studies in populations of European descent
showed that TCF7L2 is the T2D gene having the largest
risk effect to date [14,22], even if the causative variant(s)
and etiological mechanism(s) are not yet completely char-
acterized [23]. Our data are also in agreement with the
numerous previous replications of the TCF7L2-associated
SNPs mostly in white Europeans, but also in West Afri-
cans, Mexican and African Americans, Indians and Japa-
nese populations [13,15,24]. The rs7903146 variant was
also associated with an increased risk in T2D in Moroccan
subjects, suggesting a similar effect in several North Afri-
can populations [15]. However, a recent study of TCF7L2
variants in an Arab population of Saudi origin reported no
association with T2D upon analysis of two SNPs (includ-
ing rs7903146) [25].
With regard to the remaining four loci, no association
with T2D was detected for HHEX,  GCK,  KCNJ11  and
ENPP1  variants, whereas previous independent studies
reported such associations with T2D risk in several Euro-
pean white populations [9,14,26,27]. However, a lack of
association between SNPs at the HHEX locus and T2D was
also reported in a Moroccan population [27].
Minor allele frequencies of the SNPs examined in this
study compared to those reported from several other pop-
ulations with different ethnic backgrounds appeared to be
variable depending on ethnicity. For example, the fre-
quency of the Q121 allele in our study population is
Table 2: T2D association for candidate SNPs in the Tunisian study sample of 1,397 individuals
Gene SNP Genotype Control/T2D Additive model1
OR (95% CI)
P† Dominant model2
OR (95% CI)
P‡ Recessive model3
OR (95% CI)
P*
TCF7L2 rs7903146 n 511/863
CC (1/1) 181/250
CT (1/2) 235/396 1.24 (0.95–1.61) 0.135
TT (2/2) 95/217 1.56 (1.13–2.16) 0.002 1.33 (1.04–1.70) 0.023 1.38 (1.04–1.83) 0.025
MAF (T) 0.42/0.48 1.25 (1.06–1.47) 0.006#
KCNJ11 rs5219 n 503/805
CC (1/1) 250/371
CT (1/2) 213/352 1.03 (0.80–1.31) 0.399
TT (2/2) 40/82 1.23 (0.80–1.90) 0.148 1.06 (0.84–1.34) 0.630 1.22 (0.80–1.85) 0.360
MAF (T) 0.29/0.32 1.07 (0.90–1.29) 0.440#
GCKrs1799884 n 505/865
GG (1/1) 324/552
GA (1/2) 157/272 1.01 (0.79–1.30) 0.939
AA (2/2) 24/41 1.20 (0.69–2.08) 0.902 1.03 (0.81–1.32) 0.780 1.20 (0.70–2.05) 0.510
MAF (A) 0.20/0.20 1.04 (0.86–1.28) 0.640#
HHEXrs7923837 n 504/795
GG (1/1) 271/448
GA (1/2) 200/292 0.88 (0.69–1.13) 0.661
AA (2/2) 33/55 0.97 (0.60–1.58) 0.934 0.89 (0.70–1.13) 0.340 1.03 (0.64–1.65) 0.910
MAF (A) 0.26/0.25 0.93 (0.77–1.13) 0.470#
ENPP1 rs1044498 n 499/809
AA (1/1) 228/402
AC (1/2) 205/311 0.86 (0.67–1.12) 0.243
CC (2/2) 66/96 0.78 (0.54–1.14) 0.326 0.84 (0.66–1.07) 0.160 0.84 (0.59–1.19) 0.320
MAF (C) 0.33/0.31 0.88 (0.74–1.04) 0.140#
n: number of total subjects, MAF: Minor allele frequency, †,‡,*Genotype specific P values and OR are adjusted for age gender and BMI in each 
additive, dominant or recessive genetic model, respectively. #Allele-specific P values and OR of the log-additive genetic model are adjusted for age, 
gender and BMI.
1 Genetic additive model: 1/1 vs. 1/2 or 2/2 genotypes
2 Genetic dominant model: 1/1 vs. 1/2 + 2/2 genotypes
3 Genetic recessive model: 1/1 + 1/1 vs. 2/2 genotypesBMC Medical Genetics 2009, 10:33 http://www.biomedcentral.com/1471-2350/10/33
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higher (31%) than the one reported in Caucasians which
ranged from 10 to 17% [12,28], but relatively lower than
the one observed in another Tunisian cohort living in the
north of the country (47%) [29], or in African Americans
(78,5%) [30].
The extensively studied K121Q variant (rs1044498) in
ENPP1 did not reveal evidence for association with T2D in
our study from the Tunisian population. The contribution
of this variant to T2D risk in the European white popula-
tions has been established in several [12,31] but not all
[32,28] studies. These findings question the reproducibil-
ity of a real contribution to T2D risk and emphazise the
more complex diabesity component.
A recent study in another Tunisian population reported
that the ENPP1-K121Q variant may predispose to T2D
(with an OR of 1.89, 95%CI [1.13–3.15], under a domi-
nant model) [29], but the smaller sample size and ascer-
tainment of the diabetic patients analyzed could explain
this difference. In addition, it is noteworthy that in our
study we investigated a multicentric sample of T2D
patients, more representative of the Tunisian general pop-
ulation contrary to the study by Bouhaha et al. which
investigated only a group of individuals from the north of
Tunisia. In this part of country, people life style's is more
westernized with reduced physical activity and excessive
calorie intake in foods. Otherwise, these divergent results
of association, whereas a similar frequency of the Q-121
allele was observed in both studies, could be explained by
a modest contribution of the ENPP1-K121Q variant to the
risk of T2D in Tunisians at the population level, and also
in interaction with BMI and environmental factors in
modulating T2D risk, as previously reported [33].
We have to note that the present study was underpowered
to demonstrate an effect in T2D risk for HHEX,  GCK,
KCNJ11  or  ENPP1  variants similar to those previously
reported from the European diabetic cohorts [27,30,34].
Indeed, more modest genetic effects in a polygenic context
will need analysis of a larger sample size to be able to def-
initely conclude for a lack of association due to genetic
heterogeneity between specific ethnic backgrounds or to
other confounding factors, or to an underpowered associ-
ation study.
It was previously demonstrated that the genetic effects of
variants associated with either insulin secretion (like for
GCK, KCNJ11 or TCF7L2) or insulin action (for ENPP1,
ADIPOQ or PPARG) may be modulated by the obesity sta-
tus or adiposity [9,12,26,28,32,34]. Thus, the impact on
T2D risk may be largely different in obese and non obese
individuals depending on the gene variant, as this was
exemplified in adequately designed studies [12,26,28,34].
Previous genetic studies undertaken in this case-control
study from the Tunisian population have assessed the
impact of a number of gene variants on T2D risk and vas-
cular complications, such as PPARG  [35],  eNOS  [36],
MTHFR [37], IL-10 [38]. Except to the Pro12Ala variants
of PPARG which were found to be associated only to a
lower BMI among T2D patients, the other variants
showed a contribution to T2D and in part to diabetic vas-
cular complications.
Conclusion
In conclusion, our data support an effect of the widely
replicated TCF7L2 variant on T2D risk in the Arabic pop-
ulation from Tunisia, whereas the other variants tested
were not found to play a major role in T2D. In compari-
son to the European and non-European populations,
these findings can be explained by several factors, such as
a minor contribution of the studied variants that is not
detectable in this middle-sized cohort, the presence of
Arabic-specific SNPs in some loci, or a genetic heterogene-
ity of T2D between different ethnic groups, which we
already highlighted in a recent study of novel T2D-associ-
ated SNPs in several populations of different ethnic ori-
gins [27]. In this context, further GWA studies in Arabic
populations from Maghreb are required to further define
the genetic components of T2D in these populations.
Abbreviations
BMI: Body Mass Index; CI: Confidence interval; K+-ATP
channel: ATP-sensitive potassium channel; MAF: Minor
Allele Frequency; OR: Odds ratio; PCR: Polymerase Chain
Table 3: Minimum effect size detected with a statistical power of 80% in the study sample
Gene name SNP rs ID Additive model
OR (T2D)
Dominant model
OR (T2D)
recessive model
OR (T2D)
TCF7L2 rs7903146 1.25 1.44 1.43
KCNJ11 rs5219 1.26 1.37 1.62
GCK rs1799884 1.31 1.38 2.05
HHEX rs7923837 1.30 1.40 1.80
ENPP1 rs1044498 1.27 1.37 1.64
The estimation of the risk effects (OR) with a statistical power of 80% was assessed using the Quanto software.
T2D: Type 2 diabetesBMC Medical Genetics 2009, 10:33 http://www.biomedcentral.com/1471-2350/10/33
Page 6 of 7
(page number not for citation purposes)
Reaction; SNP: Single Nucleotide Polymorphism; T2D:
Type 2 Diabetes.
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